Drugs / eparlitozoviril
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07658105 | Jun 2026 → Jun 2028 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eparlitozoviril | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07658105 ↗ |
| Route | Intravenous | “7.5 mg/kg iv q3w” NCT07658105 ↗ |